ALK and non-small cell lung carcinoma: The ASCEND-4 and ASCEND-5 trials [82,83] demonstrated a statistically significant and clinically meaningful improvement in terms of PFS in favor of ceritinib versus chemotherapy respectively in TKI-naïve and in crizotinib pre-treated patients with advanced ALK-rearranged NSCLC.